Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

ClinicalTrials.gov ID: NCT00159679

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00159679. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.

Study identification

NCT ID
NCT00159679
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
167 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2004 (Type not available)
Primary completion
Not listed
Completion
Oct 2005 (Actual)
Last update posted
Jan 25, 2021

2004 – 2005

United States locations

U.S. sites
30
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Pfizer Investigational Site Hot Springs Arkansas 71913 —
Pfizer Investigational Site La Jolla California 92037 —
Pfizer Investigational Site Torrance California 90502 —
Pfizer Investigational Site Torrance California 90509 —
Pfizer Investigational Site Denver Colorado 80218 —
Pfizer Investigational Site Lake Worth Florida 33462 —
Pfizer Investigational Site Ocala Florida 34471 —
Pfizer Investigational Site Ocala Florida 34474 —
Pfizer Investigational Site Palm Beach Gardens Florida 33410 —
Pfizer Investigational Site Sunrise Florida 33351-6637 —
Pfizer Investigational Site West Palm Beach Florida 33401 —
Pfizer Investigational Site West Palm Beach Florida 33407 —
Pfizer Investigational Site Boston Massachusetts 02115 —
Pfizer Investigational Site Omaha Nebraska 68116 —
Pfizer Investigational Site Omaha Nebraska 68131 —
Pfizer Investigational Site Las Vegas Nevada 89102 —
Pfizer Investigational Site Englewood New Jersey 07631 —
Pfizer Investigational Site New Brunswick New Jersey 08901 —
Pfizer Investigational Site New Brunswick New Jersey 08903 —
Pfizer Investigational Site Albany New York 12205 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site Rochester New York 14642 —
Pfizer Investigational Site Greenville North Carolina 27834 —
Pfizer Investigational Site Toledo Ohio 43623 —
Pfizer Investigational Site Duncansville Pennsylvania 16635 —
Pfizer Investigational Site Dallas Texas 75214 —
Pfizer Investigational Site Dallas Texas 75230 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site San Antonio Texas 78229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00159679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 25, 2021 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.